Losing Weight But Not Visceral Fat: What to Do

Losing weight but not visceral fat is a common and frustrating experience: the scales move, yet your waistline stays stubbornly the same. This happens because visceral fat, the metabolically active fat stored deep within the abdominal cavity around your organs, responds differently to calorie deficits than subcutaneous fat does. Visceral fat carries far greater health risks, including type 2 diabetes, cardiovascular disease and fatty liver disease, making it a more clinically meaningful target than overall body weight. This article explains why visceral fat is so resistant, which lifestyle changes, medicines and measurements actually work, and when to seek medical advice.

Why am I losing weight but not the fat around my belly?

Weight loss without waistline reduction usually means subcutaneous fat and lean tissue are being lost rather than visceral fat, which responds differently to calorie deficits and requires specific exercise and dietary strategies to reduce.

Losing weight on the scales while your waistline barely changes may indicate that you are losing subcutaneous fat and lean tissue rather than the deeper visceral fat stored around your abdominal organs. This happens because visceral fat and subcutaneous fat respond differently to calorie deficits, exercise and hormonal signals. Visceral fat is metabolically active and releases fatty acids and inflammatory molecules directly into the portal circulation, which makes it both harmful and, in some respects, responsive to specific interventions. Research suggests that visceral fat can reduce relatively early during weight loss, but the degree of reduction varies between individuals and depends on the type and intensity of activity alongside any calorie deficit.

Several factors are associated with greater visceral fat accumulation even when overall body weight is falling. Chronic stress raises cortisol, which is linked to preferential fat storage in the visceral compartment.^[19] Poor sleep, a diet high in refined carbohydrates and ultra-processed foods, physical inactivity, and hormonal changes around the menopause or age-related changes in testosterone levels all independently promote visceral accumulation. Genetics also play a role: some people are predisposed to store a greater proportion of excess energy viscerally.

Understanding this distinction matters because overall body weight is a poor proxy for metabolic risk. Two people with identical BMIs can have very different amounts of visceral fat, and it is the visceral burden, not the number on the scales, that is most strongly associated with type 2 diabetes, cardiovascular disease and non-alcoholic fatty liver disease. Targeting visceral fat specifically, rather than weight alone, is therefore a more clinically meaningful goal.

What is visceral fat and why does it matter for your health?

Visceral fat surrounds abdominal organs, secretes pro-inflammatory cytokines and delivers free fatty acids to the liver, driving insulin resistance, cardiovascular disease, NAFLD and other serious conditions.

Visceral fat is the adipose tissue that accumulates within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries substantially greater health risks than the subcutaneous fat that sits just beneath the skin. Unlike subcutaneous fat, visceral fat is highly metabolically active. It secretes pro-inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6, and releases free fatty acids directly into the portal vein, exposing the liver to a continuous inflammatory and lipotoxic signal.

This biological activity underpins the strong associations between excess visceral fat and a cluster of conditions collectively described as metabolic syndrome:

• Insulin resistance and type 2 diabetes: visceral fat impairs insulin signalling in the liver and skeletal muscle.

• Cardiovascular disease: elevated triglycerides, reduced HDL cholesterol and raised blood pressure are all linked to visceral adiposity.

• Non-alcoholic fatty liver disease (NAFLD): portal delivery of free fatty acids promotes hepatic fat accumulation and inflammation.

• Certain cancers: observational data associate visceral obesity with colorectal, breast and endometrial cancers, though causality is complex.

• Obstructive sleep apnoea: central obesity is associated with an increased risk of obstructive sleep apnoea, with fat deposition around the neck and upper airway contributing alongside abdominal changes.

Importantly, a person can have a BMI within the so-called healthy range and still carry a clinically significant visceral fat burden, a pattern sometimes described as metabolically obese normal weight. Conversely, some individuals with a higher BMI carry relatively little visceral fat and have a more favourable metabolic profile. This is why waist circumference and waist-to-height ratio are increasingly used alongside BMI in clinical assessment. It is also worth noting that risk thresholds for waist circumference vary by ethnicity: for some South Asian, Chinese and other ethnic groups, lower thresholds are used in UK clinical practice to reflect higher metabolic risk at a given waist size.

Which lifestyle changes actually target visceral fat?

Sustained aerobic exercise combined with a calorie deficit is the most evidence-supported approach; reducing ultra-processed foods, increasing dietary fibre, improving sleep and managing stress all contribute additional benefit.

A sustained calorie deficit combined with regular aerobic exercise is the most evidence-supported approach to reducing visceral fat specifically. Research consistently shows that aerobic activity, such as brisk walking, cycling, swimming or jogging, reduces visceral fat even when total body weight changes are modest. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, and evidence from systematic reviews suggests that increasing activity volume beyond this level is associated with greater visceral fat reduction, though the optimal amount varies between individuals.^[1][2]

Resistance training adds further benefit by preserving lean muscle mass during a calorie deficit, which helps maintain resting metabolic rate and improves insulin sensitivity. A combination of aerobic and resistance exercise appears more effective than either alone for visceral fat reduction. High-intensity interval training (HIIT) has also shown promising results in some studies, though it may not suit everyone and should be introduced gradually, particularly for those with cardiovascular conditions or who are new to exercise.

Dietary composition matters as much as total calories:

• Reduce ultra-processed foods and added sugars: high intakes of free sugars, including fructose, are associated with increased hepatic fat synthesis and visceral accumulation, as outlined in the SACN Carbohydrates and Health report.^[6]

• Prioritise dietary fibre: soluble fibre from oats, legumes, vegetables and fruit feeds beneficial gut bacteria and is associated with lower visceral fat in observational studies.

• Moderate alcohol intake: alcohol has metabolic effects that promote hepatic fat accumulation and are associated with visceral fat deposition; NHS guidance recommends keeping intake within low-risk limits.

• Adequate protein: higher protein intakes support satiety and lean mass preservation during weight loss.

Sleep quality and stress management are often overlooked but are clinically important. Short sleep duration and chronically elevated cortisol are both associated with greater central adiposity. Structured relaxation techniques, cognitive behavioural approaches and sleep hygiene improvements are therefore legitimate components of a visceral fat reduction plan, though the evidence base for these as standalone interventions is less robust than for exercise and diet.

Can any medicines or treatments help reduce visceral fat in the UK?

GLP-1 receptor agonists semaglutide (Wegovy) and tirzepatide (Mounjaro) are MHRA-authorised for weight management and have shown reductions in visceral fat area in clinical trial imaging substudies; bariatric surgery produces the largest durable reductions.

Several medicines authorised in the UK have demonstrated clinically meaningful reductions in visceral fat, most notably the GLP-1 receptor agonists and the dual GIP and GLP-1 receptor agonist tirzepatide. These medicines work by mimicking incretin hormones that regulate appetite, gastric emptying and glucose metabolism, producing a sustained calorie deficit. Imaging substudies within clinical trials of semaglutide (Wegovy) and tirzepatide (Mounjaro) have reported reductions in waist circumference and visceral fat area; whether these reductions exceed what would be expected from the degree of weight loss alone requires careful interpretation of individual trial data and should not be assumed without reference to specific study findings.

In the UK, semaglutide (Wegovy) is MHRA-authorised for chronic weight management in adults with a BMI of 30 kg/m2 or above, or 27 kg/m2 or above with at least one weight-related comorbidity, and is recommended by NICE for use within a specialist weight management service.^[17][18] Tirzepatide (Mounjaro) is MHRA-authorised both for type 2 diabetes and for chronic weight management, with NICE recommending it for eligible adults within a specialist service.^[7][8] Whether an individual Integrated Care Board (ICB) commissions these treatments locally is a separate decision from NICE guidance. Bolt Pharmacy is a GPhC-registered online pharmacy (the GPhC registers pharmacies in Great Britain) offering online weight-management consultations with prescriber review and pharmacist support; Mounjaro is one option a prescriber may consider after such a consultation where it is clinically appropriate.

Other pharmacological options include orlistat, which reduces dietary fat absorption and is available on NHS prescription or over the counter at a lower dose. It does not directly target visceral fat but supports the overall calorie deficit that drives visceral fat loss. Bariatric surgery, including sleeve gastrectomy and Roux-en-Y gastric bypass, produces the largest and most durable reductions in visceral fat and is recommended by NICE for eligible patients, though access varies by ICB.

How do you measure visceral fat loss beyond the bathroom scales?

Waist circumference is the most practical clinical proxy, with NHS risk thresholds of above 94 cm for men and above 80 cm for women; waist-to-height ratio below 0.5 is also a useful indicator.

Waist circumference is the most practical clinical proxy for visceral fat and is more informative than body weight alone when tracking progress. NHS and NICE guidance uses the following thresholds to indicate increased and substantially increased metabolic risk for white European adults:

• Men: increased risk above 94 cm, substantially increased risk above 102 cm.

• Women: increased risk above 80 cm, substantially increased risk above 88 cm.

For some ethnic groups, including South Asian, Chinese and other non-white European populations, lower thresholds apply in UK clinical practice because metabolic risk is higher at a given waist size. Your GP or practice nurse can advise on the appropriate threshold for you.

Measure at the midpoint between the lower rib and the top of the hip bone (iliac crest), after a gentle exhale, without pulling the tape tight. Repeating this measurement monthly under consistent conditions gives a reliable trend even when the scales are not moving.

Waist-to-height ratio is increasingly favoured by researchers because it adjusts for body size. A ratio below 0.5 is generally considered healthy across most adult populations. To calculate it, divide your waist circumference in centimetres by your height in centimetres.

For more precise quantification, imaging techniques are available, though they are not routinely used in primary care:

• MRI scanning can directly measure visceral fat area and volume and is considered the gold standard in research settings; it does not involve ionising radiation.

• CT scanning also provides accurate visceral fat measurement but involves a radiation dose and is therefore not used for this purpose outside research or clinical need.

• DEXA (dual-energy X-ray absorptiometry) can estimate visceral fat and is available in some NHS and private settings; it involves a small radiation dose.

• Bioelectrical impedance analysis (BIA) devices, including some consumer scales and handheld monitors, estimate visceral fat but vary considerably in accuracy.

Blood tests, including fasting glucose, HbA1c, fasting lipids and liver function tests, provide indirect evidence of visceral fat burden and its metabolic consequences. Improvement in these markers alongside a falling waist circumference is a meaningful signal that visceral fat is being reduced, even when overall weight loss appears modest.

When should you speak to a GP about stubborn visceral fat?

See your GP if your waist circumference exceeds risk thresholds, lifestyle changes have not improved measurements, or you develop symptoms such as fatigue, increased thirst, elevated blood pressure or signs of sleep apnoea.

You should speak to your GP about visceral fat if your waist circumference exceeds the risk thresholds described above, particularly if you have already made sustained lifestyle changes without meaningful improvement in your measurements or metabolic blood results. A GP can arrange relevant investigations, including fasting glucose, HbA1c, a full lipid profile and liver function tests, to assess whether excess visceral fat is already affecting your metabolic health.

Certain symptoms and findings warrant a GP appointment promptly rather than waiting:

• Unexplained fatigue, increased thirst or frequent urination, which may indicate developing insulin resistance or type 2 diabetes.

• Elevated blood pressure identified at a pharmacy or home monitor.

• Abnormal liver function tests: NAFLD is often asymptomatic and discovered incidentally on blood tests; right upper abdominal discomfort can occasionally occur but is not a reliable indicator, and any persistent abdominal symptoms should be assessed by a clinician.

• Significant unintentional weight loss alongside an expanding waist, which may occasionally indicate an underlying condition rather than simple visceral fat accumulation and should be assessed promptly.

• Symptoms of obstructive sleep apnoea, including loud snoring, witnessed apnoeas or excessive daytime sleepiness.

If you are already under the care of a specialist weight management service, your clinical team is the appropriate first point of contact for concerns about treatment progress. For urgent symptoms such as severe chest pain, sudden breathlessness or collapse, call 999 immediately. For non-emergency health concerns outside GP hours, NHS 111 can provide advice.

Your GP can also discuss referral pathways to specialist weight management services, dietetic support or, where clinically appropriate, pharmacological treatment. Addressing visceral fat is a long-term process, and a structured clinical review ensures that any underlying hormonal, metabolic or psychological contributors are identified and managed alongside lifestyle measures.

Scientific References

1. Physical activity guidelines: UK Chief Medical Officers' report.
2. UK Chief Medical Officers' physical activity guidelines.
3. Physical activity guidelines for adults aged 19 to 64.
4. Semaglutide for managing overweight and obesity (TA875).
5. Semaglutide for managing overweight and obesity – Recommendations (TA875).
6. SACN statement on expressing energy, fat and carbohydrate intakes and recommendations.
7. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
8. Tirzepatide – BNF NICE.
9. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
10. Tirzepatide for managing overweight and obesity (TA1026).
11. Tirzepatide for managing overweight and obesity – Recommendations (TA1026).
12. Overweight and obesity management – Identifying and assessing overweight, obesity and central adiposity (NG246).
13. Full guideline, section 2 – Identification and classification (NG246).
14. Appendix A1: Summary of evidence from surveillance (NG246).
15. Keep the size of your waist to less than half of your height – NICE recommends.
16. Calculate your waist to height ratio.
17. First GLP-1 tablet for weight loss approved in the UK.
18. Semaglutide – BNF NICE.
19. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta. 2013..
20. A dose-response relation between aerobic exercise and visceral fat reduction. Int J Obes. 2007..
21. Combined exercise training and dietary interventions versus independent effect of exercise on ectopic fat in individuals with overweight and obesity: a systematic review, meta-analysis, and meta-regression. J Int Soc Sports Nutr. 2025..
22. Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis. JAMA Netw Open. 2024..
23. Removal of Epididymal Visceral Adipose Tissue Prevents Obesity-Induced Multi-organ Insulin Resistance in Male Mice. J Endocr Soc. 2021..

Frequently Asked Questions